As complexity in pharmaceutical development reaches new heights — especially with over 60% of recent FDA novel molecular entities falling outside traditional drug design rules — the need for advanced formulation and manufacturing strategies has never been greater. Precision medicine is no longer a future goal; it’s a present necessity. And that’s exactly where AustinPx comes in.

At the forefront of this shift is AustinPx’s KinetiSol technology, a powerful platform designed to make the “undevelopable” developable — transforming poorly soluble, highly potent small molecules into scalable, patient-ready therapies. 

Dr. Dave Miller, CSO, has spent more than 20 years in pharmaceutical R&D, helping drug developers navigate the challenges of bioavailability, permeability, and manufacturability for complex molecules.

Today, we’ll explore with Dave how CDMOs like AustinPx are empowering a new era of personalized treatment—while offering product protection strategies that help biopharma companies stand out in a competitive, cost-sensitive market.

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez

Understanding how cells interact is a critical cornerstone of modern life science, and Axion BioSystems is right at the confluence of live-cell analysis and next-generation technology. 

Axion’s Maestro and Multiwell products are helping to unlock the secrets of cellular behavior and allow the tracking of the health and function of thousands of cells at once, in real time. 

CEO Julien Bradley joined Meg on the show to discuss why understanding cellular behavior is so important - and what exciting possibilities come from Axion's vital work.

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez

Today we’re heading across the Atlantic to speak to Dr. James Field, CEO of London-based LabGenius Therapeutics.

LabGenius has a really exciting mission. James and his team of 60 scientists and engineers believe in the powerful combination of human and artificial intelligence, and are pioneering an ML-driven protein engineering platform - EVA - that can design and execute experiments for the development of next-gen antibodies, including complex multispecifics.

LabGenius has already raised over $75m in venture capital and built R&D deals with some major pharma and biotech players. After founding the company in 2012, James was named in Forbes’ ‘30 Under 30’ list for science and healthcare, and even won Innovator of the Year award from the UK’s Biotech & Biological Sciences Research Council.

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez

We made a bonus episode of From Lab To Launch to mark a special occasion: the launch of Qualio's fourth annual life science quality trends report in March 2025.

Our very own Kat and Clive dug into the report and its fascinating findings to see how life science quality teams are spending their time, what they're planning for 2025, and what headaches and frustrations they're looking to conquer this year.

Join us and dive into our report - and read the full thing at reports.qualio.com!

Note: the audio in this episode has been made using artificial intelligence

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez

As the organ transplant list continues to grow, experts in the transplant diagnostics industry are looking for ways to address the supply and demand challenges within the field. 

New tactics, like retransplantation and xenotransplantation, and new testing methods, such as HLA testing and transplant diagnostics, are being explored to boost transplant success rates and ensure more patients get the lifesaving transplants they need. 

As President of Thermo Fisher Scientific’s transplant diagnostics division, Tina Liedtky is at the cutting edge of meeting this challenge. 

She’s also passionate about addressing health equity issues, such as ingrained biases regarding gender and race, to help bridge the transplantation gap.

Tina joined Meg for a fascinating discussion about the future of transplantation, closing 'the gap', and Thermo Fisher's recent award.

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez

As more preventative approaches to health are set to take center stage, some diseases can’t be prevented but can be managed more proactively. Blood-based biomarkers, such as p-tau217, hold great promise for earlier, more proactive detection and monitoring of diseases such as Alzheimer’s, and it’s here that Quanterix plays a critical role.

Their Simoa digital health platform serves as the backbone for the majority of p-tau217 tests on the market today, reducing reliance on costly PET and CSF testing and streamlining the diagnostic journey for Alzheimer’s disease.

Mark has been a leader in the biotech space for over 2 decades, with a string of leadership roles before he joined Quanterix in 2014 and became their CSO in 2022.

Mark joined Meg on From Lab To Launch to discuss the exciting predictive power of biomarker technology, and what the future holds for spotting and treating diseases early.

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez

In this episode of From Lab to Launch by Qualio we interview Joseph Mossel, CEO and co-founder of Ibex Medical Analytics. Joseph shares his journey from computer science to leading a transformative AI-driven company in pathology. Founded in 2016, Ibex aims to provide accurate, timely, and personalized cancer diagnoses using AI technology. Joseph discusses the challenges and insights from deploying AI in clinical settings, the importance of partnerships, and the company's vision for the next few years. Tune in to learn how Ibex's innovations are reshaping cancer diagnostics and making a significant impact on patient outcomes.

https://ibex-ai.com/ 

https://www.linkedin.com/in/yossimossel/ 

00:00 Introduction to the Podcast
00:26 Meet Joseph Mossel, CEO of Ibex
01:14 The Founding and Vision of Ibex
05:59 Ibex's AI Technology and Its Impact
07:41 Challenges and Overcoming Them
09:54 AI in Cancer Diagnostics
15:12 Future of AI in Pathology
17:15 Partnerships and Collaborations
19:58 Advice for Labs and Entrepreneurs
23:29 Ensuring AI Reliability and Quality
25:48 Fun and Final Thoughts

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez

Earlier this year, Thermo Fisher Scientific opened its first clinical trial Innovation Lab in Center Valley, Pa., designed to foster a culture of collaboration by providing a dedicated space for industry partners to come together, share ideas and co-create solutions for the industry’s biggest challenges. 

The global clinical trial market was valued at over $80 billion in 2023, and that’s projected to grow by 6.5% every year until 2030. But alleviating innovation silos is the only way to move the clinical trial industry forward and tackle its current challenges. 

And it’s here that Senior Director of Innovation & Program Management Sarah Englert's mission is focused...

https://www.linkedin.com/in/sarah-blake-englert-70557421/

https://www.thermofisher.com/us/en/home.html

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez

Today we welcome Kerry Love, the co-founder of Massachusetts-based (and wonderfully named) Sunflower Therapeutics. Established in 2018, Sunflower is dedicated to advancing biologic medicines and enhancing global vaccine accessibility through cutting-edge protein manufacturing technologies.

As a women-owned organization, Sunflower has a stellar team of scientists and engineers renowned for their expertise in perfusion fermentation, purification process development, biopharmaceutical manufacturing, and quality management. Their mission-driven approach revolves around simplifying bioproduction complexities with their modular, automated, and fully integrated platform. This transformative technology empowers innovators to swiftly manufacture critical biologic products precisely where they're needed most.



https://www.linkedin.com/in/kerry-love-1a197811/ 

https://sunflowertx.com/ 

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez

Carna Health is focused on applying technology to revolutionize kidney care by unlocking the early detection and management of chronic kidney disease (CKD). They provide clinical-grade software as medical devices that deliver instant health metrics, such as creatinine, eGFR, and uACR levels, from small patient samples. Their platform integrates with existing healthcare systems and electronic healthcare records, promoting proactive and patient-centric care underpinned by accurate, real-time patient data.

CEO and co-founder Salvatore Viscomi, MD, joined Meg to talk about the Carna Health mission, where current kidney care is going wrong, and what the future holds for kidney patients.

More about Dr. Viscomi:

Dr. Viscomi is the CEO and co-founder of Carna Health, a Boston-based SaMD company focused on revolutionizing how chronic kidney disease is spotted and treated early.


https://carna.health/ 

https://www.linkedin.com/in/salvatore-viscomi/

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez